
TY  - JOUR
TI  - Educational Session 1: Blood Banking
JO  - Vox Sanguinis
VL  - 93
IS  - s2
SN  - 0042-9007
UR  - https://doi.org/10.1111/j.1423-0410.2007.00986.x
DO  - doi:10.1111/j.1423-0410.2007.00986.x
SP  - 1
EP  - 41
PY  - 2007
ER  - 

TY  - JOUR
TI  - Clinical care and other categories posters
JO  - Diabetic Medicine
VL  - 29
IS  - s1
SN  - 0742-3071
UR  - https://doi.org/10.1111/j.1464-5491.2011.03555_2.x
DO  - doi:10.1111/j.1464-5491.2011.03555_2.x
SP  - 72
EP  - 177
PY  - 2012
ER  - 

TY  - JOUR
AU  - Toledo-Pons, Nuria
AU  - Alonso-Fernández, Alberto
AU  - de la Peña, Mónica
AU  - Pierola, Javier
AU  - Barceló, Antonia
AU  - Fernández-Capitán, Carmen
AU  - Lorenzo, Alicia
AU  - Mejía Núñez, Juan Andrés
AU  - Carrera, Miguel
AU  - Soriano, Joan B.
AU  - Calvo, Néstor
AU  - Pinilla, Inmaculada
AU  - García-Río, Francisco
C7  - e12871
TI  - Obstructive sleep apnea is associated with worse clinical-radiological risk scores of pulmonary embolism
JO  - Journal of Sleep Research
JA  - J Sleep Res
VL  - n/a
IS  - n/a
SN  - 0962-1105
UR  - https://doi.org/10.1111/jsr.12871
DO  - doi:10.1111/jsr.12871
SP  - e12871
KW  - severity scores
KW  - sleep breathing disorder
KW  - venous thromboembolic disease
AB  - Summary Obstructive sleep apnea is a risk factor for pulmonary embolism, although its association with pulmonary embolism severity is unknown. Our objective was to study if obstructive sleep apnea is associated with worse pulmonary embolism severity scores and greater extent of arterial obstruction. In consecutive pulmonary embolism patients, we performed respiratory polygraphy and recorded sleep characteristics, classical risk factors for pulmonary embolism and physical activity 6?12 months after the pulmonary embolism episode. Simplified Geneva Prognostic Score and Pulmonary Embolism Severity Index were calculated at the time of the pulmonary embolism diagnosis. The Pulmonary Artery Obstruction Index and the right ventricle to left ventricle diameter ratio were measured by computed tomography pulmonary angiography. We included 120 patients, of whom 45.8% had moderate-severe obstructive sleep apnea (apnea?hypopnea index?>?15 hr?1). There was a larger proportion of moderate-severe obstructive sleep apnea patients in the third and fourth Pulmonary Artery Obstruction Index quartiles and in the III-V Pulmonary Embolism Severity Index levels compared with apnea?hypopnea index?<?15 hr?1 group. However, no differences were found between the proportion of patients with or without moderate-severe obstructive sleep apnea in their stratification by simplified Geneva Prognostic Score. The mean adjusted values of the simplified Geneva Prognostic Score, Pulmonary Embolism Severity Index and Pulmonary Artery Obstruction Index scores were higher in the apnea?hypopnea index?>?15 hr?1 group (p?<?.05). Multiple linear regression analysis identified apnea?hypopnea index as the only independent factor related to Pulmonary Artery Obstruction Index and Pulmonary Embolism Severity Index, whereas desaturation index was associated with simplified Geneva Prognostic Score. Patients with pulmonary embolism and moderate-severe obstructive sleep apnea had greater pulmonary artery obstruction as well as more pulmonary embolism severity, assessed by both the simplified Geneva Prognostic Score and the Pulmonary Embolism Severity Index, compared with patients with apnea?hypopnea index?≤?15 hr?1. Moreover, these prognostic indices were independently related to sleep parameters.
ER  - 

TY  - JOUR
TI  - Proceedings 26th Symposium ESVN-ECVN
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 28
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.12323
DO  - doi:10.1111/jvim.12323
SP  - 944
EP  - 975
PY  - 2014
ER  - 

TY  - JOUR
TI  - SUBJECT INDEX
JO  - Annals of the New York Academy of Sciences
JA  - Annals of the New York Academy of Sciences
VL  - 711
IS  - 1
SN  - 0077-8923
UR  - https://doi.org/10.1111/j.1749-6632.1994.tb00016.x
DO  - doi:10.1111/j.1749-6632.1994.tb00016.x
SP  - 201
EP  - 597
PY  - 1994
ER  - 

TY  - JOUR
TI  - Paper Abstracts
JO  - Journal of the American Geriatrics Society
VL  - 54
IS  - S4
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2006.00783.x
DO  - doi:10.1111/j.1532-5415.2006.00783.x
SP  - S1
EP  - S203
PY  - 2006
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Anaesthesia
VL  - 67
IS  - s1
SN  - 0003-2409
UR  - https://doi.org/10.1111/j.1365-2044.2011.07058.x
DO  - doi:10.1111/j.1365-2044.2011.07058.x
SP  - 6
EP  - 46
PY  - 2012
ER  - 

TY  - JOUR
TI  - European Society for Veterinary Clinical Pathology (ESVCP) 13th Annual Congress
JO  - Veterinary Clinical Pathology
JA  - Vet Clin Pathol
VL  - 41
IS  - 1
SN  - 0275-6382
UR  - https://doi.org/10.1111/j.1939-165X.2011.00375.x
DO  - doi:10.1111/j.1939-165X.2011.00375.x
SP  - E1
EP  - E16
PY  - 2012
ER  - 

TY  - JOUR
TI  - 27th Annual Conference on Peritoneal Dialysis, 13th International Symposium on Hemodialysis, and 18th Annual Symposium on Pediatric Dialysis, Denver, Colorado, February 18–20, 2007
JO  - Hemodialysis International
VL  - 11
IS  - 1
SN  - 1492-7535
UR  - https://doi.org/10.1111/j.1542-4758.2007.00160.x
DO  - doi:10.1111/j.1542-4758.2007.00160.x
SP  - 99
EP  - 144
PY  - 2007
ER  - 

TY  - JOUR
TI  - Monday, 25 July 2011
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04380_1.x
DO  - doi:10.1111/j.1538-7836.2011.04380_1.x
SP  - 1
EP  - 250
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstract Presentations from the AABB Annual Meeting San Antonio, TX, October 19–22, 2019
JO  - Transfusion
JA  - Transfusion
VL  - 59
IS  - S3
SN  - 0041-1132
UR  - https://doi.org/10.1111/trf.15462
DO  - doi:10.1111/trf.15462
SP  - 8A
EP  - 220A
PY  - 2019
ER  - 

TY  - JOUR
AU  - Kobashigawa, J.
AU  - Khush, K.
AU  - Colvin, M.
AU  - Acker, M.
AU  - Van Bakel, A.
AU  - Eisen, H.
AU  - Naka, Y.
AU  - Patel, J.
AU  - Baran, D. A.
AU  - Daun, T.
AU  - Luu, M.
AU  - Olymbios, M.
AU  - Rogers, J.
AU  - Jeevanandam, V.
AU  - Esmailian, F.
AU  - Pagani, F. D.
AU  - Lima, B.
AU  - Stehlik, J.
TI  - Report From the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 17
IS  - 10
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14354
DO  - doi:10.1111/ajt.14354
SP  - 2559
EP  - 2566
KW  - clinical research/practice
KW  - heart transplantation/cardiology
KW  - donors and donation
KW  - donors and donation: deceased
KW  - donors and donation: donor evaluation
KW  - donors and donation: extended criteria
KW  - donors and donation: standard criteria
PY  - 2017
AB  - Cardiac transplantation remains the only definitive treatment for end-stage heart failure. Transplantation rates are limited by a shortage of donor hearts. This shortage is magnified because many hearts are discarded because of strict selection criteria and concern for regulatory reprimand for less-than-optimal posttransplant outcomes. There is no standardized approach to donor selection despite proposals to liberalize acceptance criteria. A donor heart selection conference was organized to facilitate discussion and generate ideas for future research. The event was attended by 66 participants from 41 centers with considerable experience in cardiac donor selection. There were state-of-the-art presentations on donor selection, with subsequent breakout sessions on standardizing the process and increasing utilization of donor hearts. Participants debated misconceptions and established agreement on donor and recipient risk factors for donor selection and identified the components necessary for a future donor risk score. Ideas for future initiatives include modification of regulatory practices to consider extended criteria donors when evaluating outcomes and prospective studies aimed at identifying the factors leading to nonacceptance of available donor hearts. With agreement on the most important donor and recipient risk factors, it is anticipated that a consistent approach to donor selection will improve rates of heart transplantation.
ER  - 

TY  - JOUR
TI  - 46th Congress of the International Society of Paediatric Oncology (SIOP) 2014
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 61
IS  - S2
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.25314
DO  - doi:10.1002/pbc.25314
SP  - S105
EP  - S433
PY  - 2014
ER  - 

TY  - JOUR
TI  - PAPER ABSTRACTS
JO  - Journal of the American Geriatrics Society
VL  - 55
IS  - s1
SN  - 0002-8614
UR  - https://doi.org/10.1111/j.1532-5415.2007.01211.x
DO  - doi:10.1111/j.1532-5415.2007.01211.x
SP  - S1
EP  - S218
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster Session 1: Abstracts
JO  - International Journal of Stroke
VL  - 1
IS  - s1
SN  - 1747-4930
UR  - https://doi.org/10.1111/j.1747-4949.2006.00072.x
DO  - doi:10.1111/j.1747-4949.2006.00072.x
SP  - 49
EP  - 108
PY  - 2006
ER  - 

AU  - Mossad, Emad B.
AU  - Appachi, Elumalai
C7  - pp. 82-95
TI  - The Inflammatory Response and Its Modification
SN  - 9781405120609
UR  - https://doi.org/10.1002/9780470754986.ch6
DO  - doi:10.1002/9780470754986.ch6
SP  - 82-95
KW  - inflammatory response
KW  - inotropic support
KW  - pathophysiology
KW  - corticosteroids
KW  - leukocyte depletion
PY  - 2006
AB  - Summary This chapter contains section titled: Introduction Mechanisms of activation Pathophysiology of the inflammatory response Clinical effects of the inflammatory response Modification of the inflammatory response Unanswered questions
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 289–2348)
JO  - Hepatology
JA  - Hepatology
VL  - 70
IS  - S1
SN  - 9781405120609
UR  - https://doi.org/10.1002/hep.30941
DO  - doi:10.1002/hep.30941
SP  - 188
EP  - 1382
PY  - 2019
ER  - 

TY  - JOUR
C7  - e12328
TI  - IXA 2017- Abstracts of the 14th Congress of the International Xenotransplantation Association, Baltimore, USA
JO  - Xenotransplantation
JA  - Xenotransplantation
VL  - 24
IS  - 5
SN  - 9781405120609
UR  - https://doi.org/10.1111/xen.12328
DO  - doi:10.1111/xen.12328
SP  - e12328
PY  - 2017
ER  - 

TY  - JOUR
TI  - POSTERS
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 19
IS  - s2
SN  - 9781405120609
UR  - https://doi.org/10.1111/j.1468-3083.2005.01311.x
DO  - doi:10.1111/j.1468-3083.2005.01311.x
SP  - 1
EP  - 411
PY  - 2005
ER  - 

AU  - Eiges, Rachel
AU  - Zak, Naomi
AU  - Reubinoff, Benjamin E.
AU  - Irving, Charles S.
C7  - pp. 447-486
TI  - Embryonic Stem Cells
SN  - 9781119971399
UR  - https://doi.org/10.1002/9781118846193.ch25
DO  - doi:10.1002/9781118846193.ch25
SP  - 447-486
KW  - cell surface markers
KW  - drug discovery
KW  - drug evaluation
KW  - hESC-derived replacement therapy
KW  - human embryonic stem cells
KW  - inner cell mass
KW  - novel drug testing
PY  - 2005
AB  - Summary Human embryonic stem cells (hESCs) hold great promise to provide important new therapeutic approaches in treating age-associated diseases and other medical conditions due to their unique capacity for self-renewal, their pluripotency and their ability to differentiate into a broad variety of cell types. To date, numerous hESC lines have been developed and characterised. We discuss here how hESC lines are derived, their molecular and cellular properties, and how their ability to differentiate into all three embryonic germ layers is determined. We highlight some of the challenges that must be overcome to obtain and evaluate therapeutic populations from hESCs and the strategies that are being developed to enable the use of hESC-derived cell populations in clinical applications. We conclude with a discussion of clinical trials that are beginning to provide evidence for the therapeutic potential of tissue-specific differentiated populations derived from human embryonic stem cells.
ER  - 
